A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
